Acute Chest Syndrome, Anti-Bacterial Agents, Glucose-6-Phosphate Dehydrogenase Deficiency, Macrolides, Sickle Cell Disease
Conditions
Brief summary
This study looks at whether using macrolide antibiotics is helpful and safe in treating acute chest syndrome, a serious complication in people with sickle cell disease. It reviews past cases from three hospitals where patients were treated in intensive care. The goal is to understand if macrolides make a difference, what germs are involved, how useful lab tests are, and how well patients tolerate these antibiotics.
Interventions
None listed
Sponsors
Centre Hospitalier de Saint-Denis
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Adult patient (≥18 years old). * Diagnosis of acute chest syndrome (ACS). * Hospitalized in an intensive care unit (ICU). * Microbiological sampling performed (e.g., multiplex PCR, sputum culture \[ECBC\], and/or Legionella urinary antigen test). * Received empiric antibiotic therapy including a macrolide.
Exclusion criteria
* Minor patient (\<18 years old). * Acute chest syndrome not requiring ICU admission. * Acute chest syndrome without any attempt at microbiological documentation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Duration of mechanical ventilation (in days) among patients with ACS treated with empiric macrolides | 28 days |
Countries
France
Outcome results
None listed